-

07:21:11 PM

AMPH Stock News

AMPH - Amphastar Pharmaceuticals Inc

03/08/23 6:00 AM

Nasdaq : AMPH

fda approval

Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has granted approval of its New Drug Application ("NDA") for naloxone hydrochloride nasal spray 4mg, which is

RHEA-AI

neutral

02/28/23 4:05 PM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2022.

RHEA-AI

neutral

02/22/23 4:05 PM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2022 ended December 31, 2022, after the market closes on Tuesday, February 28, 2023, and will hold a conference call to

RHEA-AI

very negative

11/22/22 6:00 AM

Nasdaq : AMPH

conferences

Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th

RHEA-AI

neutral

11/10/22 4:05 PM

Nasdaq : AMPH

conferences

Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Administration Center, will participate in an Analyst-Moderated fireside chat at the 2022 Jefferies London

RHEA-AI

neutral

11/07/22 4:05 PM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2022. Third

RHEA-AI

neutral

10/28/22 6:00 AM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2022 ended September 30, 2022, after the market closes on Monday, November 7, 2022, and will hold a conference call to

RHEA-AI

neutral

09/02/22 6:00 AM

Nasdaq : AMPH

conferences

Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operations,

RHEA-AI

neutral

08/16/22 6:00 AM

Nasdaq : AMPH

fda approval

Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled

RHEA-AI

very positive

08/01/22 6:05 AM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, after the market closes on Monday, August 8, 2022, and will hold a conference call to discuss its

RHEA-AI

neutral

AMPH Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.amphastar.com
CeoJack Zhang
Security nameAmphastar Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees1761
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address11570 6th St
StateCalifornia
CityRancho Cucamonga
Zip91730-6025
CountryUS
Phone19099809484

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.